After a strong endorsement in the National Comprehensive Cancer Network guidelines, Dendreon's first-of-its-kind prostate cancer vaccine Provenge appears well positioned for broad insurance coverage and take-up with physicians. Commercial carriers that had been left gasping at the autologous cellular immunotherapy's $93,000 annual price tag may now feel obliged to provide coverage after a May 12 update to the NCCN practice guidelines.According to the update, Provenge (sipuleucel-T) is recommended...